288
Participants
Start Date
November 21, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
Rifabutin
Rifabutin (Rb) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
Delamanid
Delamanid (D or DLM) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
Bedaquiline
Bedaquiline is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
Moxifloxacin
Moxifloxacin is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
Pyrazinamide
Pyrazinamide is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ). Pyrazinamide is part of control regimen (HRZE).
Isoniazid
Isoniazid is part of control regimen (HRZE).
Rifampin
Rifampin is part of control regimen (HRZE).
Ethambutol
Ethambutol is part of control regimen (HRZE).
TBTC Site 09 University of Cape Town Lung Institute (Pty) Ltd, Mowbray
TBTC Site 76 CAB-V. Can Tho Province, Vietnam - Thot Not District TB Unit, Can Tho
TBTC Site 26 Seattle & King County TB Control Program, Seattle
McGill University Health Centre, Montreal
Vancouver, British Columbia Centre for Disease Control, Vancouver
TBTC Site 30 Uganda-Case Western Reserve Research Collaboration, Kampala
TBTC Site 67 GHESKIO centers IMIS, Port-au-Prince
TBTC Site 45 Les Centres Gheskio (INLR), Port-au-Prince
Tuberculosis Trials Consortium
NETWORK
Centers for Disease Control and Prevention
FED